EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics

Fangfang Yan, Yang Liu, Heng-Huan Lee, Wei Wang, Joseph McIntosh, Yijing Li, Jovanny Vargas, Yue Fei, Sairah Ahmed iD, Lukas M Simon, Michael Wang iD

American Journal of Hematology · 2026-07 · 101 (7) · 1632-1649

DOI: 10.1002/ajh.70304 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 17.04.2026. Verfasst von Fangfang Yan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Drug Resistance, Neoplasm, Pyrimidines, Protein Kinase Inhibitors. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Steve and Nancy Fox Research Funds, NCI NIH HHS, CPRIT SINGLE CORE Facilities Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pirtobrutinib (PBN), a non‐covalent BTK inhibitor, has been approved by the FDA for relapsed/refractory mantle cell lymphoma (MCL); however, resistance to PBN has been observed. To dissect the molecular dynamics driving PBN resistance, we performed integrative single‐cell multi‐omic profiling (scRNA‐seq, scATAC‐seq, and scDNA‐seq) on longitudinal MCL patient samples. Our analyses revealed both genetic and non‐genetic routes of resistance: In some patients, resistance involves sequential copy number gains (e.g., 1q, 2p, and 8q) accompanied by transcriptomic reprogramming and epigenetic alterations, whereas in others, resistance occurs through non‐genetic mechanisms driven by transcriptional and epigenetic remodeling. Integration of scATAC‐seq and scRNA‐seq enabled gene regulatory network inference and in silico perturbation analysis, highlighting RAD21 and SMC3, core components of the cohesin complex, as chromatin regulators whose downregulation may re‐sensitize cells to PBN. A stem‐like malignant B cell population enriched in resistant samples exhibited features of metabolic reprogramming and epithelial‐mesenchymal transition. Together, our findings highlight heterogeneous, multi‐layered mechanisms of PBN resistance and suggest chromatin regulators as potential therapeutic targets to overcome PBN resistance in MCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellDrug Resistance, NeoplasmPyrimidinesProtein Kinase InhibitorsHumansMultiomicsSingle-Cell AnalysisEpigenesis, GeneticGene Expression Regulation, NeoplasticPyrazoles

Substanzen

PyrimidinesProtein Kinase InhibitorspirtobrutinibPyrazoles

Autor:innen und Institutionen

  • Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Therapeutic Innovation Center, Baylor College of Medicine, Houston, Texas, USA.
  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Sairah Ahmed, Michael Wang

Förderung

  • Steve and Nancy Fox Research Funds
  • NCI NIH HHS
  • CPRIT SINGLE CORE Facilities Grant
  • NIH Shared Instrument Grant

Zitieren

APA

Yan, F., Liu, Y., Lee, H. H., Wang, W., McIntosh, J., Li, Y., Vargas, J., Fei, Y., Ahmed, S., Simon, L. M., & Wang, M. (2026). Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics. American Journal of Hematology, 101(7), 1632-1649. https://doi.org/10.1002/ajh.70304

Vancouver

Yan F, Liu Y, Lee HH, Wang W, McIntosh J, Li Y, et al. Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics. American Journal of Hematology. 2026;101(7):1632-1649. doi:10.1002/ajh.70304

BibTeX
@article{Yan2026,
  author = {Yan, Fangfang and Liu, Yang and Lee, Heng-Huan and Wang, Wei and McIntosh, Joseph and Li, Yijing and Vargas, Jovanny and Fei, Yue and Ahmed, Sairah and Simon, Lukas M and Wang, Michael},
  title = {Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single‐Cell Multi‐Omics},
  journal = {American Journal of Hematology},
  year = {2026},
  volume = {101},
  number = {7},
  pages = {1632--1649},
  doi = {10.1002/ajh.70304}
}
Kostenlos starten →